T. Zhu

发表

The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect

S. Brun, Y. Chiu, G. Hanna, 2007, Journal of acquired immune deficiency syndromes.

Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.

B. He, T. Zhu, F. Lee, 2002, Drug metabolism and disposition: the biological fate of chemicals.

C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.

T. Maurer, M. Leininger, C. Steppan, 2010, Bioorganic & medicinal chemistry letters.

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T‐Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients

Stanley B. Cohen, J. Keirns, A. Kivitz, 2016, Clinical pharmacology in drug development.

Evaluation of Pharmacokinetic/Pharmacodynamic Relationships of PD-0162819, a Biotin Carboxylase Inhibitor Representing a New Class of Antibacterial Compounds, Using In Vitro Infection Models

M. Kuhn, D. Hanna, Shawn M Mehrens, 2011, Antimicrobial Agents and Chemotherapy.

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

J. Grosset, C. K. Stover, S. Tyagi, 2009, American journal of respiratory and critical care medicine.

Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo.

Y. Zhao, T. Zhu, Shunying Liu, 2021, European journal of medicinal chemistry.

Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

J. Grosset, C. K. Stover, S. Tyagi, 2008, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular Mycobacterium tuberculosis in Ex Vivo Whole-Blood Cultures of Patients with Pulmonary Tuberculosis

A. Diacon, R. Wallis, T. Zhu, 2014, Antimicrobial Agents and Chemotherapy.

Pulmonary Tuberculosis Whole-Blood Cultures of Patients with Ex Vivo Mycobacterium tuberculosis in Metabolite against Intracellular Sutezolid ( PNU-100480 ) and Its Major Analysis of the Bactericidal Activities of Pharmacokinetic / Pharmacodynamic Population

A. Diacon, T. Zhu, S. O. Friedrich, 2014 .

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis

K. Papp, T. Zhu, C. Schwabe, 2018, Biopharmaceutics & drug disposition.

Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects

J. Keirns, T. Zhu, J. Garg, 2017, Clinical Pharmacokinetics.

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

Bo Feng, Zhuang Miao, A. Kalgutkar, 2011, Drug Metabolism and Disposition.

Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV

L. Fraenkel, M. Yin, Taisheng Li, 2015, Osteoporosis International.

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

R. Wallis, Vikas Kumar, D. Paige, 2010, Antimicrobial Agents and Chemotherapy.

The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.

W. Denny, S. Hagen, J. Smaill, 2007, Bioorganic & medicinal chemistry letters.

A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore

Alla Karnovsky, J Richard Miller, V Hayden Thomas, 2009, Proceedings of the National Academy of Sciences.

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

J. A. Spicer, P. Ellis, W. Denny, 2016, Journal of medicinal chemistry.

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism

R Scott Obach, P. Glue, B. Damle, 2011, Journal of clinical pharmacology.

Drug metabolism and drug interactions: potential application to antituberculosis drugs.

A. Vaz, V. Sahasrabudhe, Susanna Tse, 2015, The Journal of infectious diseases.

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

P. Ellis, A. Bridges, D. W. Fry, 2008, Molecular Cancer Therapeutics.

Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans

J. Ansquer, Tong Zhu, Jean-Claude Ansquer, 2010, Journal of clinical pharmacology.

Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology

T. Maurer, A. Ghosh, M. Leininger, 2011, The AAPS Journal.

Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects

S. Swan, J. Keirns, K. Lasseter, 2016, Clinical pharmacology in drug development.

A novel simultaneous modeling approach to estimate linearity of pharmacokinetic parameters, including saturation of intestinal efflux, in the rat.

V. Sahasrabudhe, J. Williams, J. Koup, 2005, Journal of pharmacological and toxicological methods.

AB0363 Coadministration of asp015k, a novel janus kinase inhibitor, with methotrexate demonstrates tolerability and lack of pharmacokinetic interactions in patients with rheumatoid arthritis

V. Chindalore, T. Zhu, K. Oda, 2013 .

Simultaneous intravenous and intramiddle-ear dosing to determine cefditoren influx and efflux clearances in middle ear fluid in freely moving chinchillas.

R. Sawchuk, T. Zhu, B. Cheung, 2003, Journal of pharmaceutical sciences.

Challenges of Psychiatry Drug Development and the Role of Human Pharmacology Models in Early Development—A Drug Developer's Perspective

T. Zhu, 2021, Frontiers in Psychiatry.

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies

G. Marek, Lauren Benner, T. Uz, 2020, Clinical Pharmacokinetics.

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia

G. Marek, P. Maruff, G. Light, 2020, Neuropsychopharmacology.

The Effect of Verapamil, a P‐Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once‐Daily JAK Inhibitor

J. Keirns, T. Zhu, J. Garg, 2017, Clinical pharmacology in drug development.

Rutin protects against cyclophosphamide induced immunological stress by inhibiting TLR4-NF-κB-mediated inflammation and activating the Nrf2- mediated antioxidant responses

Yang Song, Hong Wang, T. Zhu, 2022, Pharmacological Research - Modern Chinese Medicine.

An efficient approach for the rapid assessment of oral rat exposures for new chemical entities in drug discovery.

Kjell Johnson, Hyo-Kyung Han, Kjell Johnson, 2006, Journal of pharmaceutical sciences.

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis

Wenhui Zhang, V. Chindalore, T. Zhu, 2020, Clinical Drug Investigation.

THU0227 Pooled Analysis of Clinical Safety Data for ASP015K, a Novel Jak Inhibitor in Development for Treatment of Autoimmune Diseases

G. Ball, S. Wisseh, T. Zhu, 2013 .

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

Mark J. Mitton-Fry, R. Wallis, Vikas Kumar, 2010, Antimicrobial Agents and Chemotherapy.

ABT‐335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans

B. Hosmane, W. Awni, T. Zhu, 2009, Journal of clinical pharmacology.